But when the researchers analyzed the data, they found that fluoxetine appeared not to provide meaningful benefits for ...
Postpartum depression descended on Kristina Leos like a heavy fog that separated her from everyone she loved. She could see ...
Knowable Magazine reports on a new blood test, myLuma, predicting postpartum depression risk with over 80% accuracy, aiding ...
A fast-acting treatment pill can help new moms with postpartum depression in just a couple of weeks — and it’s so new, many ...
The mid-stage failure was unexpected to analysts at BMO Capital Markets, who viewed ‘770 as mostly derisked given its similar ...
BrainsWay announced today that the FDA granted a label expansion for its deep transcranial magnetic stimulation (Deep TMS) ...
The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong ...
Similarly, in a warning about compounded finasteride, the United States Food and Drug Administration stated in April 2025 ...
Another of the psychiatry drugs Neurocrine Biosciences licensed from Takeda has stumbled in the clinic. | Another of the ...
Investing.com -- Brainsway Ltd (NASDAQ:BWAY) stock surged 5% in premarket trading Thursday after the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback